208 related articles for article (PubMed ID: 21934710)
1. Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer.
Kwiatkowski F; Dessenne P; Laquet C; Petit MF; Bignon YJ
Eur J Hum Genet; 2012 Feb; 20(2):141-7. PubMed ID: 21934710
[TBL] [Abstract][Full Text] [Related]
2. [Informing the family: emotions and attitudes of oncogenetic counselees for familial breast/ovarian and/or colon cancer risk].
Kwiatkowski F; Laquet C; Dessenne P; Bignon YJ
Bull Cancer; 2015 Feb; 102(2):162-73. PubMed ID: 25636360
[TBL] [Abstract][Full Text] [Related]
3. Psychosocial outcomes and counselee satisfaction following genetic counseling for hereditary breast and ovarian cancer: A patient-reported outcome study.
Oberguggenberger A; Sztankay M; Morscher RJ; Sperner-Unterweger B; Weber I; Hubalek M; Kemmler G; Zschocke J; Martini C; Egle D; Dünser M; Gamper E; Meraner V
J Psychosom Res; 2016 Oct; 89():39-45. PubMed ID: 27663109
[TBL] [Abstract][Full Text] [Related]
4. Genetic counseling in hereditary breast/ovarian cancer in Israel: psychosocial impact and retention of genetic information.
DiCastro M; Frydman M; Friedman I; Shiri-Sverdlov R; Papa MZ; Goldman B; Friedman E
Am J Med Genet; 2002 Aug; 111(2):147-51. PubMed ID: 12210341
[TBL] [Abstract][Full Text] [Related]
5. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
[TBL] [Abstract][Full Text] [Related]
6. Genetic counseling does not fulfill the counselees' need for certainty in hereditary breast/ovarian cancer families: an explorative assessment.
Vos J; Menko FH; Oosterwijk JC; van Asperen CJ; Stiggelbout AM; Tibben A
Psychooncology; 2013 May; 22(5):1167-76. PubMed ID: 22777929
[TBL] [Abstract][Full Text] [Related]
7. Informing relatives about their hereditary or familial cancer risk: study protocol for a randomized controlled trial.
de Geus E; Aalfs CM; Verdam MG; de Haes HC; Smets EM
Trials; 2014 Mar; 15():86. PubMed ID: 24649895
[TBL] [Abstract][Full Text] [Related]
8. Psychological distress in women seeking genetic counseling for breast-ovarian cancer risk: the contributions of personality and appraisal.
Audrain J; Schwartz MD; Lerman C; Hughes C; Peshkin BN; Biesecker B
Ann Behav Med; 1997; 19(4):370-7. PubMed ID: 9706364
[TBL] [Abstract][Full Text] [Related]
9. Brief assessment of parents' attitudes toward testing minor children for hereditary breast/ovarian cancer genes: development and validation of the Pediatric BRCA1/2 Testing Attitudes Scale (P-TAS).
Peshkin BN; DeMarco TA; Garber JE; Valdimarsdottir HB; Patenaude AF; Schneider KA; Schwartz MD; Tercyak KP
J Pediatr Psychol; 2009 Jul; 34(6):627-38. PubMed ID: 18385162
[TBL] [Abstract][Full Text] [Related]
10. How to facilitate psychosocial adjustment in women tested for hereditary breast or ovarian cancer susceptibility? Insights from network analysis.
Brédart A; Dick J; Cano A; Robieux L; De Pauw A; Schmutzler R; Stoppa-Lyonnet D; Dolbeault S; Kop JL
Psychooncology; 2020 Mar; 29(3):550-556. PubMed ID: 31823434
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.
Arver B; Haegermark A; Platten U; Lindblom A; Brandberg Y
Fam Cancer; 2004; 3(2):109-16. PubMed ID: 15340261
[TBL] [Abstract][Full Text] [Related]
13. BRACAVENIR - impact of a psychoeducational intervention on expectations and coping in young women (aged 18-30 years) exposed to a high familial breast/ovarian cancer risk: study protocol for a randomized controlled trial.
Kwiatkowski F; Dessenne P; Laquet C; Daures JP; Gay-Bellile M; Bignon YJ
Trials; 2016 Oct; 17(1):509. PubMed ID: 27769293
[TBL] [Abstract][Full Text] [Related]
14. Exploring attitudes, beliefs, and communication preferences of Latino community members regarding BRCA1/2 mutation testing and preventive strategies.
Kinney AY; Gammon A; Coxworth J; Simonsen SE; Arce-Laretta M
Genet Med; 2010 Feb; 12(2):105-15. PubMed ID: 20061960
[TBL] [Abstract][Full Text] [Related]
15. The withdrawal from oncogenetic counselling and testing for hereditary and familial breast and ovarian cancer. A descriptive study of an Italian sample.
Caruso A; Vigna C; Maggi G; Sega FM; Cognetti F; Savarese A
J Exp Clin Cancer Res; 2008 Nov; 27(1):75. PubMed ID: 19025627
[TBL] [Abstract][Full Text] [Related]
16. Comparing Outcomes of Genetic Counseling Options in Breast and Ovarian Cancer: An Integrative Review
.
Fournier DM; Bazzell AF; Dains JE
Oncol Nurs Forum; 2018 Jan; 45(1):96-105. PubMed ID: 29251290
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
[TBL] [Abstract][Full Text] [Related]
18. Genetic counseling, testing, and screening for breast and ovarian cancer: practical and social considerations.
Khabele D; Runowicz CD
Curr Womens Health Rep; 2002 Jun; 2(3):163-9. PubMed ID: 12099190
[TBL] [Abstract][Full Text] [Related]
19. Cancer genetics knowledge and beliefs and receipt of results in Ashkenazi Jewish individuals receiving counseling for BRCA1/2 mutations.
Kelly K; Leventhal H; Marvin M; Toppmeyer D; Baran J; Schwalb M
Cancer Control; 2004; 11(4):236-44. PubMed ID: 15284715
[TBL] [Abstract][Full Text] [Related]
20. Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
Vos J; Gómez-García E; Oosterwijk JC; Menko FH; Stoel RD; van Asperen CJ; Jansen AM; Stiggelbout AM; Tibben A
Psychooncology; 2012 Jan; 21(1):29-42. PubMed ID: 21072753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
